Sponsors (106)
Introduced February 12, 2025 by James Varni Panetta · Last progress February 12, 2025
The bill improves federal clarity, surveillance, and enforcement tools to reduce illicit xylazine harms, but it risks restricting legitimate medical/veterinary access, raising compliance and enforcement costs, and increasing criminal-justice impacts that could disproportionately affect marginalized communities.
Federal law enforcement, prosecutors, and courts get clearer legal authority and definitions for xylazine (including salts/isomers), improving ability to interdict supply, prosecute trafficking, and apply consistent penalties.
Healthcare providers and public-health agencies will have better surveillance and reporting of xylazine-related overdoses and exposures, enabling more informed clinical and community responses.
Placing xylazine under stricter federal controls should reduce availability for misuse and support coordinated interdiction efforts, potentially lowering community-level harms from contaminated or co-used drug supplies.
People who possess or use xylazine (including low-income and racial-ethnic-minority communities) face increased criminal enforcement and penalties, raising risks of more arrests, prosecutions, and unequal impacts.
Legitimate medical and veterinary access to xylazine could be restricted or made more administratively burdensome, creating uncertainty for patients, providers, and animal-care operations during implementation.
The change will impose compliance, testing, reporting, and implementation costs on federal, state, and local governments and on manufacturers, pharmacies, and healthcare facilities, ultimately borne in part by taxpayers and service providers.
Based on analysis of 7 sections of legislative text.
Classifies xylazine as Schedule III, adds definitions, delays select compliance tasks, directs sentencing review, and requires two federal reports on illicit xylazine.
Classifies xylazine — including its salts and isomers — as a Schedule III controlled substance, adds a statutory definition, and creates transitional rules for possession, labeling, and practitioner requirements to ease the shift into scheduling. It directs federal agencies to help manufacturers with necessary filings, orders the U.S. Sentencing Commission to review penalties for offenses involving xylazine, and requires two reports to Congress on illicit xylazine prevalence and trafficking.